Crittenden JR, Cantuti-Castelvetri I, Saka E, Keller-McGandy CE, Hernandez LF, Kett LR, Young AB, Standaert DG, Graybiel AM. Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2892-6. PubMed.
Recommends
Please login to recommend the paper.
Comments
Harvard Medical School, Brigham and Women's Hospital
Lindquist and collaborators show that overexpression of orthologs of the familial PD gene PARK9 in yeast and worm, and overexpression of human PARK9 in rat primary midbrain cultures suppresses α-synuclein (SNCA) toxicity in theses models. The genetic interaction between the two PD genes SNCA (PARK1) and ATP13A2 (PARK9) is exciting. This provocative observation suggests for the first time that these two previously unconnected PD genes may be involved in one single disease pathway.
This raises a number of questions: What precisely is this pathway and what exactly are the roles α-synuclein and ATP13A2 play in it? Is it ER-to-Golgi transport as the authors hint at, or could it be a lysosomal or other process? Unfortunately, little is known about the biological role of ATP13A2 other than its classification as a P-class ion pump and that it seems to localize to lysosomal membranes in COS7 cells. It will be important to clarify the subcellular localization and the biochemistry of this interaction, and substantiate the relevance of this link between SNCA and ATP13A2 for the human disease, in human dopamine cells, and in the substantia nigra of patients with PD.
Exposure to manganese-containing fumes may make welders more prone to develop PD. In a second part of the study, Gitler et al. speculate about an additional role for PARK9 in this process. They indicate that yeast ATP13A2 modulates sensitivity of yeast cells to manganese exposure. This is an interesting hypothesis—but a lot more research is needed to clinch this.
View all comments by Clemens Scherzer